Contact this trialFirst, we need to learn more about you.
Alkylating Agent
Ruxolitinib + Chemotherapy for Breast Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing a new drug called Ruxolitinib combined with three other cancer drugs to treat Inflammatory Breast Cancer (IBC). It targets patients who may not respond well to typical treatments. Ruxolitinib works by blocking a pathway that cancer cells need to grow and helps other drugs be more effective. Ruxolitinib has been beneficial in the treatment of myelofibrosis.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service